^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IGF2BP1 overexpression

    i
    Other names: Insulin Like Growth Factor 2 MRNA Binding Protein 1, IMP-1, Insulin-Like Growth Factor 2 MRNA-Binding Protein 1, Coding Region Determinant-Binding Protein, IGF-II MRNA-Binding Protein 1, IGF2 MRNA-Binding Protein 1, Zipcode-Binding Protein 1, VICKZ Family Member 1, CRD-BP, VICKZ1, CRDBP, ZBP-1, IMP1, ZBP1, Insulin-Like Growth Factor 2 MRNA Binding Protein 1 DeltaN CRDBP, Insulin-Like Growth Factor 2 MRNA Binding Protein 1, IGF II MRNA Binding Protein 1, IGF2BP1
    Entrez ID:
    10642
    1m
    Anillin contributes to prostate cancer progression through the regulation of IGF2BP1 to promote c-Myc and MAPK signaling. (PubMed, Am J Cancer Res)
    Meanwhile, we discovered that ANLN can stabilize the proto-oncogene c-Myc and activate the MAPK signaling pathway through IGF2BP1. These findings indicate that ANLN could be a potential therapeutic target in PCa.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • ANLN (Anillin Actin Binding Protein)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    4ms
    IGF2BP1 facilitates non-small cell lung cancer progression by regulating the KIF2A-mediated Wnt/β-catenin pathway. (PubMed, Funct Integr Genomics)
    KIF2A exerted the same functions as IGF2BP1 via the Wnt/β-catenin signaling. In conclusion, IGF2BP1 enhances NSCLC malignant progression by stabilizing KIF2A to modulate the Wnt/β-catenin pathway.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    4ms
    BIRC5 facilitates cisplatin-chemoresistance in a m A-dependent manner in ovarian cancer. (PubMed, Cancer Med)
    The regulation of its expression and the stability of its mRNA were influenced by m A modifications involving both METTL3 and IGF2BP1. These insights presented BIRC5 as a promising potential therapeutic target for addressing cisplatin resistance in OC.
    Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • METTL3 (Methyltransferase Like 3)
    |
    BIRC5 expression • IGF2 overexpression • IGF2BP1 overexpression
    |
    cisplatin
    6ms
    N-Methyladenosine (mA) Reader IGF2BP1 Accelerates Gastric Cancer Development and Immune Escape by Targeting PD-L1. (PubMed, Mol Biotechnol)
    Moreover, the IGF2BP1 overexpression enhanced the stability of PD-L1 mRNA, thereby deteriorating the immune escape of gastric cancer cells. Collectively, these results describe a novel regulatory mechanism of IGF2BP1 by regulating PD-L1 through mA epigenetic modification, which might provide insights for gastric cancer immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    PD-L1 overexpression • IGF2BP1 overexpression
    7ms
    RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia. (PubMed, J Exp Clin Cancer Res)
    Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • TNFA (Tumor Necrosis Factor-Alpha) • IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2 overexpression • IGF2BP1 overexpression • RUNX1 overexpression
    8ms
    Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells. (PubMed, Exp Hematol Oncol)
    Elevated expression of IGF2BP1 is a frequent event in ESCC tissues and might be a candidate biomarker for the disease. IGF2BP1 overexpression promotes the invasion and migration of ESCC cells by activating the INHBA-Smad2/3 pathway, providing a potential therapeutic target for ESCC patients with high expression of IGF2BP1.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • G3BP1 (G3BP Stress Granule Assembly Factor 1)
    |
    IGF2 elevation • IGF2BP1 overexpression
    1year
    IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression. (PubMed, Cancer Lett)
    More importantly, BTYNB, a recently identified IGF2BP1 inhibitor, exerted promising anti-tumor efficacy in a patient-derived xenograft (PDX) model, and IGF2BP1 conditional knockout (cKO) reduced the tumor burden. These results demonstrate the crucial role of IGF2BP1 in iCCA progression via mA-dependent modification, highlighting IGF2BP1 as a potential therapeutic target in iCCA.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IGF2 (Insulin-like growth factor 2) • MMP2 (Matrix metallopeptidase 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2BP1 overexpression
    1year
    LINC00858 facilitates formation of hepatic metastases from colorectal cancer via regulating the miR-132-3p/IGF2BP1 axis. (PubMed, Biol Chem)
    LINC00858 could facilitate CRC tumor growth and hepatic metastases. LINC00858 induced CRC hepatic metastases via regulating miR-132-3p/ IGF2BP1, and this study may deliver a new diagnostic marker for the disease.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • MIR132 (MicroRNA 132)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    1year
    EMX2OS targeting IGF2BP1 represses Wilms' tumour stemness,epithelial-mesenchymal transition and metastasis. (PubMed, J Genet)
    The in vivo tumour growth, stemness and EMT were repressed by EMX2OS through the interaction with IGF2BP1. In conclusion, EMX2OS acted as a tumour suppressor for WT by interacting with IGF2BP1, which might be a novel target for WT diagnosis and therapy.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • NANOG (Nanog Homeobox) • MX2 (MX Dynamin Like GTPase 2)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    over1year
    IGF2BP3 Expression Correlates with Poor Survival in Primary and Relapsed Pediatric B-ALL (B-cell Acute Lymphoblastic Leukemia) in an Indian Cohort (ASH 2022)
    This is in line with our previous work which shows that IGF2BP3 overexpression leads to progenitor expansion in the mouse marrow and is essential for development of MLL-AF4 induced leukemogenesis. Our work also provides strong rationale for targeting this machinery for therapy in B-ALL.
    Clinical
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3)
    |
    MLL translocation • IGF2BP1 overexpression • FTO expression
    over1year
    SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis. (PubMed, J Gynecol Oncol)
    SP1-induced MCF2L-AS1 promoted ovarian cancer cisplatin-resistance through activation of IGF2/MEK/ERK pathway via interacting with IGF2BP1.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • ANXA5 (Annexin A5) • MCF2L-AS1 (MCF2L Antisense RNA 1)
    |
    IGF2BP1 overexpression
    |
    cisplatin
    2years
    Long Non-coding RNA HOXA11-AS Facilitates Proliferation of Lung Adenocarcinoma Cells via Targeting the Let-7c-5p/IGF2BP1 Axis. (PubMed, Front Genet)
    Experiments on mice confirmed that HOXA11-AS facilitated LUAD cell growth in vivo through regulating the let-7c-5p/IGF2BP1 axis. HOXA11-AS promoted LUAD cell proliferation by targeting let-7c-5p/IGF2BP1, which could be potential molecular targets for LUAD.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • HOXA11 (Homeobox A11) • Let-7c (MicroRNA Let-7c)
    |
    IGF2 overexpression • IGF2BP1 overexpression • HOXA11 overexpression
    over2years
    Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma (PubMed, Shanghai Kou Qiang Yi Xue)
    IGF2BP1 is significantly associated with cisplatin resistance in oral squamous cell carcinoma. IGF2BP1 can promote cisplatin resistance of oral squamous cells by activating downstream Akt signaling pathway.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    |
    cisplatin
    over2years
    Long Non-Coding RNA THOR Depletion Inhibits Human Non-Small Cell Lung Cancer Cell Growth. (PubMed, Front Oncol)
    At last we show that Lnc-THOR is overexpressed in multiple NSCLC tissues and established/primary NSCLC cells. Collectively, these results highlighted the ability of Lnc-THOR in promoting NSCLC cell growth by associating with IGF2BP1, suggesting that Lnc-THOR represents a promising therapeutic target of NSCLC.
    Journal
    |
    GLI1 (GLI Family Zinc Finger 1) • IGF2 (Insulin-like growth factor 2) • SOX9 (SRY-Box Transcription Factor 9) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2BP1 overexpression
    over2years
    Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. (PubMed, Int J Mol Sci)
    Overexpression of IGF2BP1 promoted the colony-forming capacity and 5-fluorouracil and etoposide resistance in CRC cells. Here, IGF2BP1 was an independent poor prognostic marker in CRC patients and contributed to aggressive phenotypes in CRC cell lines.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    |
    5-fluorouracil • etoposide IV